Spinal Restoration, Inc. Announces the Submission of the Investigational Device Exemption (IDE) Pilot Study Results for the Biostat(R) System
6/9/2009 9:07:41 AM
AUSTIN, Texas--(BUSINESS WIRE)--Spinal Restoration, Inc. announced today it has submitted the 6-month primary endpoint results from an ongoing 2-year IDE pilot study of the Biostat® System for treatment of chronic low back pain due to symptomatic internal disc disruptions to the Food and Drug Administration. The results of this three site, 15 patient pilot study are a key component of Spinal Restoration’s petition to initiate a larger pivotal trial.